Overview

A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.

Phase:

Phase 3

Details

Lead Sponsor:

Nantes University Hospital

Treatments:

Aspirin
Tissue Plasminogen Activator